(Q74611892)
Statements
Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors (English)
R L Drengler
J G Kuhn
L J Schaaf
G I Rodriguez
M A Villalona-Calero
L A Hammond
J A Stephenson
S Hodges
M A Kraynak
B A Staton
G L Elfring
P K Locker
L L Miller
D D Von Hoff
M L Rothenberg
1 February 1999